UnitedHealth forecasts annual profit below estimates

UnitedHealth (UNH) reinstated its full-year profit forecast at a significantly reduced level of at least $16 per share, sharply below its prior guidance of $26-$26.50 and analysts' lowered expectations of $20.91. This revision, alongside a second-quarter adjusted profit miss ($4.08 vs. $4.48 estimate), stems from higher-than-anticipated medical expenditures and rising costs within its government-backed plans, prompting a 5% premarket share decline. The development underscores significant challenges for new CEO Stephen Hemsley, although the company reiterated its expectation to return to earnings growth in 2026.

Analysis

UnitedHealth (UNH) has reinstated its full-year profit forecast at a level significantly below consensus, signaling persistent and severe cost pressures. The new guidance of at least $16 per share for 2025 is a drastic reduction from the prior range of $26 to $26.50 and falls well short of analysts' already lowered expectations of $20.91. This negative outlook is substantiated by the company's second-quarter performance, where adjusted profit of $4.08 per share missed the $4.48 estimate. The primary driver for both the earnings miss and the guidance cut is higher-than-anticipated medical expenditures within its government-backed plans, a headwind that has also impacted industry peers. The 5% premarket share decline reflects the market's reaction to the scale of these challenges, which now confront CEO Stephen Hemsley, who was recently restored to the role. While management reiterated its expectation for a return to earnings growth in 2026, the severity of the current issues casts uncertainty on the near-to-medium term outlook.

Key Decisions for Investors

• Investors should immediately revise their 2025 earnings models downward to reflect the new guidance floor of $16 per share, anticipating continued negative sentiment and stock price volatility.
• The primary metric to monitor is the company's medical loss ratio, as any further deterioration in medical cost trends will directly threaten future profitability and could invalidate the current guidance.
• Consider the heightened execution risk associated with the new management, as the ability to stabilize costs and deliver on the promised 2026 earnings growth rebound is now a critical factor for any long-term investment thesis.